Eloxx Pharmaceuticals Q3 EPS $(0.11) Up From $(0.16) YoY
Eloxx Pharmaceuticals (NASDAQ:ELOX) reported quarterly losses of $(0.11) per share. This is a 31.25 percent increase over losses of $(0.16) per share from the same period last year.
Eloxx Pharma US Patent & Trademark Office Abstract For Co.’s ‘Large scale preparation of pseudo-trisaccharide aminoglycosides and of intermediates thereof’
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=5031&f=G&l=50&d=PTXT&p=101&S1=20211005&OS=20211005&RS=20211005
Eloxx Stock Moves Higher On Fast Track Tag For Cystic Fibrosis Candidate
The FDA has granted Fast Track designation Eloxx Pharmaceuticals Inc’s (NASDAQ:ELOX) ELX-02, a drug candidate intended to treat cystic fibrosis patients…
Eloxx Pharmaceuticals Shares Spike Higher; Co Announces Fast Track Designation For ELX-02 For Treatment Of Cystic Fibrosis Patients With Nonsense Mutations
Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ELX-02, a drug candidate intended to treat cystic fibrosis patients with
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios’ Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 17)